肿瘤细胞治疗研究
ALL SOURCES
The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.
我们的研究结果表明，肿瘤细胞特异性共表达 SLC7A11/PD-L1 与结外 NK/T 细胞淋巴瘤（ENKTL）的不良预后相关，提示双靶向治疗可能提高这些患者的疗效。
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
无化疗方案培门冬酶联合信迪利单抗在新诊断的晚期NKTCL中有效且安全。
The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vascul
这些发现表明，CD47和CTLA4的双重靶向通过协调“吃我”和“别吃我”信号、重塑免疫微环境以及促进肿瘤血管正常化，发挥抗肿瘤作用。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
